Ali-Reza Biglarnia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali-Reza Biglarnia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Amir Sedigh
Department of Transplantation, Surgical Sciences, Uppsala University Hospital Uppsala University Uppsala, Sweden [ protected
1 shared publicationAnders Magnusson
Department of Transplantation, Surgical Sciences, Uppsala University Hospital Uppsala University Uppsala, Sweden [ protected
1 shared publicationBengt von Zur-Mühlen
Department of Transplantation, Surgical Sciences, Uppsala University Hospital Uppsala University Uppsala, Sweden [ protected
1 shared publication- Bo Nilsson
Department of Immunology, Genetics, and Pathology (IGP), Rudbeck Laboratory C5:3, Uppsala University, Uppsala, Sweden
1 shared publication Erik Larsson
Department of Transplantation, Surgical Sciences, Uppsala University Hospital Uppsala University Uppsala, Sweden [ protected
1 shared publicationGunnar Tufveson
Department of Transplantation, Surgical Sciences, Uppsala University Hospital Uppsala University Uppsala, Sweden [ protected
1 shared publication
Latest Publications
- 1 January 2015
- Published by Springer Nature
- Vol. 865, 211-233
Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective
The humoral barrier in transplant biology is the result of preformed donor-specific antibodies (DSAs), directed either against human leukocyte antigens (HLA) or non-HLA antigens such as blood group (ABO) molecules. The term “sensitization” applies to patients carrying these antibodies. Transplantation is widely accepted as a life-saving opportunity for patients with terminal end-organ disease. However, in sensitized patients, transplant outcome is hampered by antibody-mediated rejection (AMR) as a consequence of DSA exposure. Furthermore, sensitized patients have limited access to “matched” organs from the both living and deceased donor pool. Considering the crucial role of the complement system in the pathophysiology of AMR and the availability of complement intervention therapeutics, there is a growing interest in complement-targeting strategies. This review highlights the emerging importance of monitoring and modulation of the complement system in the context of enabling transplantation across humoral incompatibility in sensitized recipients with preformed anti-HLA or natural anti-ABO antibodies. It also discusses the significance of the complement system in the induction of accommodation and further emphasizes current and future perspectives of novel complement therapeutics.
- 1 January 2015
- Published by Springer Nature
- Vol. 865, 211-233
Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective
The humoral barrier in transplant biology is the result of preformed donor-specific antibodies (DSAs), directed either against human leukocyte antigens (HLA) or non-HLA antigens such as blood group (ABO) molecules. The term “sensitization” applies to patients carrying these antibodies. Transplantation is widely accepted as a life-saving opportunity for patients with terminal end-organ disease. However, in sensitized patients, transplant outcome is hampered by antibody-mediated rejection (AMR) as a consequence of DSA exposure. Furthermore, sensitized patients have limited access to “matched” organs from the both living and deceased donor pool. Considering the crucial role of the complement system in the pathophysiology of AMR and the availability of complement intervention therapeutics, there is a growing interest in complement-targeting strategies. This review highlights the emerging importance of monitoring and modulation of the complement system in the context of enabling transplantation across humoral incompatibility in sensitized recipients with preformed anti-HLA or natural anti-ABO antibodies. It also discusses the significance of the complement system in the induction of accommodation and further emphasizes current and future perspectives of novel complement therapeutics.
- 1 August 2014
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 260 (2) , e5-e7
Utilization of Small Pediatric Donors Including Infants for Pancreas and Kidney Transplantation
- 1 August 2014
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 260 (2) , e5-e7
Utilization of Small Pediatric Donors Including Infants for Pancreas and Kidney Transplantation